Posted by Michael Wonder on 05 Feb 2021
FDA grants Actinogen rare paediatric disease designation in Fragile X syndrome
5 February 2021 - Actinogen is pleased to announce that the United States FDA has granted Actinogen’s drug Xanamem rare paediatric disease designation for the treatment of Fragile X syndrome.
Fragile X syndrome is a rare and serious genetic disorder, typically diagnosed in children but with life-long symptoms, that is characterised by a range of development problems including behavioural problems, autism features, severe anxiety, cognitive impairment and disordered sleep.
